112 related articles for article (PubMed ID: 33676358)
21. Management of Immune Checkpoint Inhibitor Toxicities: A Review and Clinical Guideline for Emergency Physicians.
Hryniewicki AT; Wang C; Shatsky RA; Coyne CJ
J Emerg Med; 2018 Oct; 55(4):489-502. PubMed ID: 30120013
[TBL] [Abstract][Full Text] [Related]
22. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.
Sun X; Roudi R; Dai T; Chen S; Fan B; Li H; Zhou Y; Zhou M; Zhu B; Yin C; Li B; Li X
BMC Cancer; 2019 Jun; 19(1):558. PubMed ID: 31182061
[TBL] [Abstract][Full Text] [Related]
23. Sex Differences in Tolerability to Anti-Programmed Cell Death Protein 1 Therapy in Patients with Metastatic Melanoma and Non-Small Cell Lung Cancer: Are We All Equal?
Duma N; Abdel-Ghani A; Yadav S; Hoversten KP; Reed CT; Sitek AN; Enninga EAL; Paludo J; Aguilera JV; Leventakos K; Lou Y; Kottschade LA; Dong H; Mansfield AS; Manochakian R; Adjei AA; Dronca RS
Oncologist; 2019 Nov; 24(11):e1148-e1155. PubMed ID: 31036771
[TBL] [Abstract][Full Text] [Related]
24. Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study.
Cortellini A; Buti S; Santini D; Perrone F; Giusti R; Tiseo M; Bersanelli M; Michiara M; Grassadonia A; Brocco D; Tinari N; De Tursi M; Zoratto F; Veltri E; Marconcini R; Malorgio F; Garufi C; Russano M; Anesi C; Zeppola T; Filetti M; Marchetti P; Botticelli A; Antonini Cappellini GC; De Galitiis F; Vitale MG; Sabbatini R; Bracarda S; Berardi R; Rinaldi S; Tudini M; Silva RR; Pireddu A; Atzori F; Chiari R; Ricciuti B; Iacono D; Migliorino MR; Rossi A; Porzio G; Cannita K; Ciciarelli V; Fargnoli MC; Ascierto PA; Ficorella C
Oncologist; 2019 Jun; 24(6):e327-e337. PubMed ID: 30796151
[TBL] [Abstract][Full Text] [Related]
25. Rapid temporal improvement of pembrolizumab-induced pneumonitis using the anti-TNF-α antibody infliximab.
Sawai Y; Katsuya Y; Shinozaki-Ushiku A; Iwasaki A; Fukayama M; Watanabe K; Nagase T
Drug Discov Ther; 2019 Jul; 13(3):164-167. PubMed ID: 31257354
[TBL] [Abstract][Full Text] [Related]
26. [No hair loss, but colitis or pneumonitis: unique side effects of immune checkpoint inhibitors for cancer].
Steenbruggen TG; van den Heuvel MM; Blank CU; van Dieren JM; Haanen JB; Kok M
Ned Tijdschr Geneeskd; 2016; 160():A9873. PubMed ID: 27438388
[TBL] [Abstract][Full Text] [Related]
27. Prospective evaluation of the prognostic value of immune-related adverse events in patients with non-melanoma solid tumour treated with PD-1/PD-L1 inhibitors alone and in combination with radiotherapy.
Schweizer C; Schubert P; Rutzner S; Eckstein M; Haderlein M; Lettmaier S; Semrau S; Gostian AO; Frey B; Gaipl US; Zhou JG; Fietkau R; Hecht M
Eur J Cancer; 2020 Nov; 140():55-62. PubMed ID: 33045663
[TBL] [Abstract][Full Text] [Related]
28. Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced Melanoma: A Systematic Review and Network Meta-analysis.
Chang CY; Park H; Malone DC; Wang CY; Wilson DL; Yeh YM; Van Boemmel-Wegmann S; Lo-Ciganic WH
JAMA Netw Open; 2020 Mar; 3(3):e201611. PubMed ID: 32211869
[TBL] [Abstract][Full Text] [Related]
29. Can CT distinguish hypersensitivity pneumonitis from idiopathic pulmonary fibrosis?
Lynch DA; Newell JD; Logan PM; King TE; Müller NL
AJR Am J Roentgenol; 1995 Oct; 165(4):807-11. PubMed ID: 7676971
[TBL] [Abstract][Full Text] [Related]
30. Supportive care for patients undergoing immunotherapy.
Rapoport BL; van Eeden R; Sibaud V; Epstein JB; Klastersky J; Aapro M; Moodley D
Support Care Cancer; 2017 Oct; 25(10):3017-3030. PubMed ID: 28707167
[TBL] [Abstract][Full Text] [Related]
31. Immune checkpoint inhibitor-associated interstitial lung diseases correlate with better prognosis in patients with advanced non-small-cell lung cancer.
Sugano T; Seike M; Saito Y; Kashiwada T; Terasaki Y; Takano N; Hisakane K; Takahashi S; Tanaka T; Takeuchi S; Miyanaga A; Minegishi Y; Noro R; Kubota K; Gemma A
Thorac Cancer; 2020 Apr; 11(4):1052-1060. PubMed ID: 32096610
[TBL] [Abstract][Full Text] [Related]
32. Radiological manifestations of immune-related adverse effects observed in patients with melanoma undergoing immunotherapy.
Sidhu P; Menzies AM; Long G; Carlino M; Lorens S; Kapoor R
J Med Imaging Radiat Oncol; 2017 Dec; 61(6):759-766. PubMed ID: 29024572
[TBL] [Abstract][Full Text] [Related]
33. Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1.
Mekki A; Dercle L; Lichtenstein P; Marabelle A; Michot JM; Lambotte O; Le Pavec J; De Martin E; Balleyguier C; Champiat S; Ammari S
Eur J Cancer; 2018 Jun; 96():91-104. PubMed ID: 29698933
[TBL] [Abstract][Full Text] [Related]
34. Characterization of pneumonitis in patients with advanced non-small cell lung cancer treated with everolimus (RAD001).
White DA; Schwartz LH; Dimitrijevic S; Scala LD; Hayes W; Gross SH
J Thorac Oncol; 2009 Nov; 4(11):1357-63. PubMed ID: 19745764
[TBL] [Abstract][Full Text] [Related]
35. Deep learning for classifying fibrotic lung disease on high-resolution computed tomography: a case-cohort study.
Walsh SLF; Calandriello L; Silva M; Sverzellati N
Lancet Respir Med; 2018 Nov; 6(11):837-845. PubMed ID: 30232049
[TBL] [Abstract][Full Text] [Related]
36. Neurological toxicities associated with immune-checkpoint inhibitors.
Touat M; Talmasov D; Ricard D; Psimaras D
Curr Opin Neurol; 2017 Dec; 30(6):659-668. PubMed ID: 28938341
[TBL] [Abstract][Full Text] [Related]
37. Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study.
Nigro O; Pinotti G; De Galitiis F; Di Pietro FR; Giusti R; Filetti M; Bersanelli M; Lazzarin A; Bordi P; Catino A; Pizzutilo P; Galetta D; Marchetti P; Botticelli A; Scagnoli S; Russano M; Santini D; Torniai M; Berardi R; Ricciuti B; De Giglio A; Chiari R; Russo A; Adamo V; Tudini M; Silva RR; Bolzacchini E; Giordano M; Di Marino P; De Tursi M; Rijavec E; Ghidini M; Vallini I; Stucci LS; Tucci M; Pala L; Conforti F; Queirolo P; Tanda E; Spagnolo F; Cecchi F; Bracarda S; Macrini S; Santoni M; Battelli N; Fargnoli MC; Porzio G; Tuzi A; Suter MB; Ficorella C; Cortellini A
Eur J Cancer; 2020 Jul; 134():19-28. PubMed ID: 32454395
[TBL] [Abstract][Full Text] [Related]
38. Pulmonary Adverse Events in Cancer Immunotherapy: Case Studies of CT Patterns.
Bocchini G; Imperato MC; Valente T; Guarino S; Lieto R; Massimo C; Muto E; Romano F; Scaglione M; Sica G; Vitagliano Torre D; Masala S; Bocchino M; Rea G
Diagnostics (Basel); 2024 Mar; 14(6):. PubMed ID: 38535033
[TBL] [Abstract][Full Text] [Related]
39. Imaging Features of Toxicities by Immune Checkpoint Inhibitors in Cancer Therapy.
Widmann G; Nguyen VA; Plaickner J; Jaschke W
Curr Radiol Rep; 2016; 5(11):59. PubMed ID: 28959504
[TBL] [Abstract][Full Text] [Related]
40. Clinical and Histopathologic Features of Immune Checkpoint Inhibitor-related Pneumonitis.
Larsen BT; Chae JM; Dixit AS; Hartman TE; Peikert T; Roden AC
Am J Surg Pathol; 2019 Oct; 43(10):1331-1340. PubMed ID: 31162288
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
